OmniAb Inc(OABI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:01 PM ET (Korea 10/29 05:01)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.36 | Insider Own | 18.49% | Shs Outstand | 145.4M | Perf Week | 7.43% |
| Market Cap | 0.77B | Forward P/E | - | EPS next Y | 25.76% | Insider Trans | - | Shs Float | 118.5M | Perf Month | 11.39% |
| Enterprise Value | 0.73B | PEG | - | EPS next Q | -0.13 | Inst Own | 49.25% | Short Float | 7.21% | Perf Quarter | 165.33% |
| Income | -0.04B | P/S | 19.96 | EPS this Y | 36.59% | Inst Trans | -4.21% | Short Ratio | 5.29 | Perf Half Y | 288.24% |
| Sales | 0.04B | P/B | 2.95 | EPS next 5Y | 44.02% | ROA | -15.11% | Short Interest | 8.54M | Perf YTD | 185.41% |
| Book/sh | 1.79 | P/C | 14.77 | EPS past 3/5Y | -29.62% -14.88% | ROE | -16.95% | 52W High | -2.76% ($5.43) | Perf Year | 240.65% |
| Cash/sh | 0.36 | P/FCF | - | Sales past 3/5Y | -31.89% -14.39% | ROIC | -16.09% | 52W Low | 306.15% ($1.30) | Perf 3Y | 17.86% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 40.54% | Gross Margin | 36.4% | Volatility(W/M) | 6.78% 7.31% | Perf 5Y | -47.09% |
| Dividend TTM | - | EV/Sales | 19.1 | Sales Y/Y TTM | 67.01% | Oper. Margin | -125.96% | ATR (14) | 0.32 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.72 | EPS Q/Q | 69.59% | Profit Margin | -115.12% | RSI (14) | 63.63 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.8 | Sales Q/Q | 244.24% | SMA20 | 10.77% ($4.77) | Beta | 0.61 | Target Price | $8.21 |
| Payout | - | Debt/Eq | 0.07 | Earnings | 2026/10/30 | SMA50 | 14.36% ($4.62) | Rel Volume | 0.97 | Prev Close | $4.96 |
| Employees | 89 | LT Debt/Eq | 0.06 | EPS/Sales Surpr. | 58.33% 185.85% | SMA200 | 97.75% ($2.67) | Avg Volume(3M) | 1.61M | Price | $5.28 |
| IPO | 2021/9/30 | Option/Short | Yes/Yes | Trades | 8457 | Volume | 1,570,238 | Change | 6.45% |
🧬 OmniAb (OABI) is a biotech technology platform company that supports the discovery of antibody-based drug candidates. Its core business centers on licensing antibody discovery technologies to pharmaceutical and biotech partners and receiving milestone payments and royalties when the candidates advance to clinical and commercialization stages.
Over the past 1 year, on the higher side
3% below its 1-year high.
Traded about as much as usual. That is 97% of its average volume.
Next earnings report: October 30
2 days to go.
OABI has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +36.6% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,996. Peers typically go for $1,261.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -47.1%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 49.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #181 of 594 in the industry
Based on market cap of $768M.
FAQ
What kind of company is OABI?
OABI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of OABI?
The market cap of OABI is approximately $768M, ranking 2,799 within its sector.
What is the 52-week high and low for OABI?
OABI has recorded a 52-week high of $5.43 and a low of $1.30.
